Compounds > 5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine
Page last updated: 2024-09-03

5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine and remacemide

5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine has been researched along with remacemide in 1 studies

Compound Research Comparison

Studies
(5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine)		Trials
(5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine)		Recent Studies (post-2010)
(5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine)		Studies
(remacemide)		Trials
(remacemide)		Recent Studies (post-2010) (remacemide)
100193245

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anger, T; Madge, DJ; Mulla, M; Riddall, D1

Reviews

1 review(s) available for 5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine and remacemide

ArticleYear
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
    Journal of medicinal chemistry, 2001, Jan-18, Volume: 44, Issue:2

    Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Models, Molecular; Mutation; Nerve Tissue Proteins; Neuroprotective Agents; Protein Binding; Sodium Channel Blockers; Sodium Channels; Stroke

2001